Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Persistent or Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
NCT00023712Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2001
- Primary completion
- Jan 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in ovarian epithelial cancer, primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Nov 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00023712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023712.